What is HC Wainwright’s Forecast for CRBU Q1 Earnings?

Caribou Biosciences, Inc. (NASDAQ:CRBU) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Caribou Biosciences in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.43) per share for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.94) EPS.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The firm had revenue of $2.08 million for the quarter, compared to analysts’ expectations of $2.11 million.

A number of other research analysts have also recently issued reports on the company. Bank of America decreased their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Citigroup reduced their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $10.33.

Caribou Biosciences Stock Up 5.2 %

Caribou Biosciences stock opened at $1.00 on Friday. Caribou Biosciences has a 12-month low of $0.95 and a 12-month high of $5.77. The business’s 50-day moving average price is $1.30 and its two-hundred day moving average price is $1.75. The stock has a market cap of $93.00 million, a PE ratio of -0.61 and a beta of 2.34.

Institutional Trading of Caribou Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Erste Asset Management GmbH acquired a new position in shares of Caribou Biosciences in the third quarter worth approximately $28,000. Centric Wealth Management acquired a new position in shares of Caribou Biosciences in the fourth quarter worth approximately $27,000. Intech Investment Management LLC acquired a new position in shares of Caribou Biosciences in the third quarter worth approximately $43,000. Russell Investments Group Ltd. lifted its stake in shares of Caribou Biosciences by 859.0% in the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock worth $38,000 after acquiring an additional 21,416 shares during the period. Finally, MetLife Investment Management LLC lifted its stake in shares of Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock worth $39,000 after acquiring an additional 9,148 shares during the period. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.